GB201021979D0 - New compound - Google Patents
New compoundInfo
- Publication number
- GB201021979D0 GB201021979D0 GB201021979A GB201021979A GB201021979D0 GB 201021979 D0 GB201021979 D0 GB 201021979D0 GB 201021979 A GB201021979 A GB 201021979A GB 201021979 A GB201021979 A GB 201021979A GB 201021979 D0 GB201021979 D0 GB 201021979D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- inhibitor
- antagonist
- agonist
- receptor
- ccr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 abstract 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 abstract 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 229940124638 COX inhibitor Drugs 0.000 abstract 1
- 229940124003 CRTH2 antagonist Drugs 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 abstract 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 abstract 1
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 abstract 1
- 101100532722 Ovis aries SCNN1B gene Proteins 0.000 abstract 1
- 239000012826 P38 inhibitor Substances 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000002559 chemokine receptor antagonist Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 oxa-4,9-diazaspiro[5.5]undecan-9-yl Chemical group 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 101150082646 scnn1a gene Proteins 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Butyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H- benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(3-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-5 oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a PDE4 inhibitor; a PPAR? agonist; a protease inhibitor; a p38 inhibitor, a selective glucocorticoid receptor agonist (SEGRA), a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201021979A GB201021979D0 (en) | 2010-12-23 | 2010-12-23 | New compound |
| PCT/GB2011/052560 WO2012085583A1 (en) | 2010-12-23 | 2011-12-22 | New compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201021979A GB201021979D0 (en) | 2010-12-23 | 2010-12-23 | New compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201021979D0 true GB201021979D0 (en) | 2011-02-02 |
Family
ID=43599002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201021979A Ceased GB201021979D0 (en) | 2010-12-23 | 2010-12-23 | New compound |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201021979D0 (en) |
| WO (1) | WO2012085583A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (en) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| CN105142673B8 (en) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity |
| TWI643853B (en) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | a salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activity |
| TWI641373B (en) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | Salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having activity of both a muscarinic receptor antagonist and a β2 adrenergic receptor agonist |
| TW201517906A (en) | 2013-07-25 | 2015-05-16 | Almirall Sa | Combinations comprising MABA compounds and corticosteroids |
| TW201617343A (en) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities |
| CN109195975B (en) * | 2016-09-30 | 2022-01-04 | 四川海思科制药有限公司 | Diazaspiro [5.5] undecane derivative and application thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB432097A (en) | 1935-03-28 | 1935-07-19 | John Rea Chance | Improvements in brackets for the handles of perambulators |
| EP1234878A4 (en) | 1999-11-24 | 2003-06-11 | Takeda Chemical Industries Ltd | USE OF A GENES RELATED TO A DISEASE |
| CA2395179A1 (en) | 1999-12-24 | 2001-07-05 | F. Hoffmann-La Roche Ag | Nitrile derivatives as cathepsin k inhibitors |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| CO5300399A1 (en) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| AR028948A1 (en) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | NEW COMPOUNDS |
| ES2281434T3 (en) | 2000-08-14 | 2007-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | REPLACED PIRAZOLS. |
| SE0100902D0 (en) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0102617D0 (en) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| SE0102616D0 (en) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| SE0104251D0 (en) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Novel compounds |
| SE0104331D0 (en) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Novel compounds |
| AR038703A1 (en) | 2002-02-28 | 2005-01-26 | Novartis Ag | DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3 |
| AR039385A1 (en) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA |
| SE0300092D0 (en) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0300091D0 (en) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (en) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| EP1633734A2 (en) | 2003-06-19 | 2006-03-15 | Genaera Corporation | Mucin synthesis inhibitors |
| JP4690319B2 (en) | 2003-06-30 | 2011-06-01 | メルク フロスト カナダ リミテツド | Cathepsin cysteine protease inhibitor |
| SE0301963D0 (en) | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
| SA04250253B1 (en) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd |
| SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| EP2251327B1 (en) | 2003-11-19 | 2014-02-12 | Array Biopharma, Inc. | Heterocyclic inhibitors of mek |
| ES2292130T3 (en) | 2004-05-04 | 2008-03-01 | Warner-Lambert Company Llc | PIRIDO (2,3-D) PIRIMIDIN-7-PIRROLIL-SUBSTITUTED WAVES AND DERIVED FROM THEMSELVES AS THERAPEUTIC AGENTS. |
| SE0401762D0 (en) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| PL1831149T3 (en) | 2004-12-23 | 2012-06-29 | Galderma Res & Dev | Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics |
| WO2006091112A1 (en) | 2005-02-22 | 2006-08-31 | Genesis Reasearch And Development Corporation Limited | Compositions for the delivery of rna interference molecules and methods for their use |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007082956A1 (en) | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| UY30267A1 (en) | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS |
| WO2007123939A2 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| WO2007144198A2 (en) | 2006-06-16 | 2007-12-21 | Umc Utrecht Holding B.V. | Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases |
| JP2009543860A (en) | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | Novel tricyclic spiropiperidine compounds, their synthesis and their use as chemokine receptor activity modulators |
| US7981898B2 (en) | 2006-09-07 | 2011-07-19 | Parion Sciences, Inc. | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| WO2008064136A2 (en) | 2006-11-17 | 2008-05-29 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
| SE530201C2 (en) | 2006-12-18 | 2008-03-25 | Nilar Int Ab | Collision detecting circuit breaker system for battery stack in electric or hybrid vehicle, releases pressure applied to bipolar battery stack by strut in event of collision |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| SA08280783B1 (en) | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | Pyridopyrimidine Derivatives as PDE4 Inhibitors |
| RU2479580C2 (en) | 2007-06-27 | 2013-04-20 | Астразенека Аб | Pyrazinone derivatives and use thereof in treatment of lung diseases |
| WO2009044200A1 (en) | 2007-10-04 | 2009-04-09 | Astrazeneca Ab | Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity |
| TWI445705B (en) | 2008-05-20 | 2014-07-21 | Astrazeneca Ab | A carbazole derivative substituted with a phenyl group and a benzodifluorenyl group |
| GB0913342D0 (en) * | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
-
2010
- 2010-12-23 GB GB201021979A patent/GB201021979D0/en not_active Ceased
-
2011
- 2011-12-22 WO PCT/GB2011/052560 patent/WO2012085583A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012085583A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201021992D0 (en) | Compound | |
| GB201021979D0 (en) | New compound | |
| EA201000702A1 (en) | SOME DERIVATIVES 2-PYRAZINONE AND THEIR APPLICATION AS NEUTROFIL ELASTASIS INHIBITORS | |
| ME02323B (en) | Spiro substituted compounds as angiogenesis inhibitors | |
| NO20064156L (en) | Indazole carboxamide compounds as 5-HT 4 receptor agonists | |
| NO20073259L (en) | New 4-arylaminopyndondenate as MEK inhibitors of hyperproliferative disorders | |
| ECSP099567A (en) | COMBINATIONS OF BENZOTIAZOLONA AGONIST OF ADRENERGIC RECEIVERS BETA 2 | |
| EA200702541A1 (en) | ETHYL ESTER POLYMORPHORMS 3 - [(2 - {[4- (HEXILOXYCARBONYLAMINOIMINOMETHYL) PHENYLAMINO] METHYL} -1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL) PYRIDIN-2-I-BENYMIDAZOL-5-CARBONYL) Pyridine-2-I-IHYDIHYRODYOL-5-CARBONYL-Pyridine-2-I-BPHYHIRODYOL-5-CARBONYL-Pyridine-2-I-pyrimidazole-5-Carbonyl) Pyridine-2-I-Pyrihydromethyl-1-Benzimidazole-5-Carbonyl) Pyridine-2-I-Pyrihydromethylamino-5-Carbonyl) Pyridine-2-I-Benzimidazole-5-Carbonyl) Pyridine-2-I-Pyrimidazole-5-Carbonyl) Pyridine-2-I; | |
| JO3021B1 (en) | 4-[4-({[ 4- chloro-3- (trifluoromethyl) phenyl] carbamoyl}lamino)-3- fluoromethyl]-N-methylpyridine -2- carboxamide monohydrate | |
| WO2011053938A8 (en) | Methods and compositions for treating cancer | |
| MX2007005205A (en) | Sulfonyl-substituted bicyclic compounds as modulators of ppar. | |
| CY1113734T1 (en) | CHEMICAL COMPOUNDS | |
| WO2007022380A3 (en) | Bis-aryl amide compounds and methods of use | |
| BR0313923A (en) | 3- (Sulfonamidoethyl) indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases | |
| CL2010001608A1 (en) | Compounds derived from 2- (3- (5-oxo-4,5-dihydro-pyrazin-2-yl) -phenyl) -4,5-dihydro-2h-isoquinolin-1-one and 2- (3- (5 -oxo-4,5-dihydro-pyrazin-2-yl) -phenyl) -3,4-dihydro-2h-isoquinolin-1-one, kinase inhibitors; pharmaceutical composition; Useful in the treatment of inflammatory and / or immune pathological conditions. | |
| DK1485378T3 (en) | Piperazinyl, piperidinyl and morpholinyl derivatives as novel inhibitors of histone deacetylase | |
| SV2005002148A (en) | "MODULATING COMPOUNDS OF THE C-KIT ACTIVITY AND USES OF THE SAME" | |
| ATE526318T1 (en) | FARNESOID-X RECEPTOR AGONISTS | |
| WO2006044823A3 (en) | Heteroaryl-substituted alkyne compounds and method of use | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| EA200870376A1 (en) | Benzothiazols possessing activity in relation to the histamine h3-receptor | |
| CN111601791A (en) | EZH2 inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof | |
| TN2009000160A1 (en) | PYRAZOLINE DERIVATIVES USEFUL AS ANTAGONISTS OF MINERALOCORTICOID RECEPTORS | |
| MA28279A1 (en) | INDOLE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS, IN PARTICULAR IKK2 INHIBITORS | |
| NO20081001L (en) | Derivatives of carboxamide as antagonists of muscarinic receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |